Method Specific

Progestogen-only Implants

CEU Statement: Intravascular insertion of Nexplanon® - June 2016

01 June 2016

This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD to healthcare professionals in the UK regarding a small number of reports of Nexplanon contraceptive implants inadvertently inserted into blood vessels.

This document is up-to-date

Progestogen-only Injectables

Combined Hormonal Contraception

CEU Statement: Use of COC and risk of VTE (May 2015)

01 May 2015

The BMJ today publishes the findings of a large UK observational study by Vinogradova et al looking at the association between combined oral contraception (COC) and risk of venous thromboembolism (VTE). The authors conducted two nested case-control studies utilising data from the UK QResearch and Clinical Practice Research Datalink (CPRD) databases.

This document is up-to-date

CEU Statement: Missed pills (May 2011)

01 May 2011

In 2005, the Faculty of Sexual and Reproductive Healthcare (FSRH) updated the original guidance on missed combined oral contraceptive pills (COCs)1 following publication of revised evidence-based recommendations from the World Health Organization.

This document is up-to-date

CEU Statement: COC and Stroke (Nov 2014)

01 November 2014

Faculty of Sexual and Reproductive Healthcare (FSRH) guidance on Combined Hormonal Contraception1 (CHC), including combined oral contraceptive pills (COC), states that available data regarding the risk of stroke related to the use of CHC is conflicting. Although a meta-analysis reported a two-fold increase in the risk of ischaemic stroke with the use of low dose COCs, other studies have not found that COC use results in a statistically significant increased risk of ischaemic or haemorrhagic stroke.

This document is up-to-date

FSRH Statement: Venous Thromboembolism (VTE) and Hormonal Contraception Nov 2014

01 March 2014

This statement updates and replaces the Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline No. 40 on the same topic. It summarises Faculty of Sexual and Reproductive Healthcare (FSRH) recommendations and relevant information found within FSRH clinical guidance.

This document is up-to-date

CEU Statement: COC and Mood (August 2014)

01 August 2014

There have been recent discussions in the media (press and radio) about combined oral contraception and its effect on mood. While mood changes and depression are often cited as a side effect of oral contraceptive use, and a reason for discontinuation, evidence supporting an association is generally lacking.

This document is up-to-date

CEU Statement: Response to new reports of link between COC and Glaucoma (November 2013)

01 November 2013

Following a presentation at the annual meeting of the American Academy of Ophthalmology a number of media reports have reported a possible link between use of combined oral contraception (COC) and glaucoma. There is limited data investigating combined hormonal contraceptives on glaucoma. One cohort study suggested that 5 or more years of COC use was associated with a 25% increase in the risk of glaucoma. Two UK cohort studies did not find consistent evidence of an increased risk.

This document is up-to-date

CEU Statement: Response to recommendations from the Pharmacovigilance Risk Assessment Committee (PRAC) in relation to prescribing of CHC (October 2013)

01 October 2013

Following concerns in France about the risk of thromboembolism associated with the constituents of different combined hormonal contraceptives, the European Medicines Agency (EMA) started a review of the benefits and risks of the socalled third and fourth generation (newer) combined hormonal contraceptives (CHCs) in February of this year.

This document is up-to-date

CEU Statement: Strengthening of Warnings about use of Dianette and other brands of co-cyprindiol (June 2013)

01 June 2013

Following a recent safety review, a letter has been issued to healthcare professionals from the manufacturers of Dianette® and other cyproterone acetate 2 mg/ ethinylestradiol 35 mcg (co-cyprindiol) products. The review by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) followed concerns about the risk of thrombosis associated with co-cyprindiol. With the agreement of the EMA and Medicines and Healthcare products Regulatory Authority (MHRA), a letter has been issued to raise awareness of the thrombosis risks and the outcome of the review.

This document is up-to-date

Barrier Methods

Male and Female Sterilisation

CEU Statement: Response to the BMJ paper by Mao et. al. (October 2015)

01 October 2015

A large observational study from the United States found that the risk of unintended pregnancy after Essure sterilisation was similar to that after surgical sterilisation. However just over 2% of women who had Essure sterilisation required a further operation related to the sterilisation procedure within a year.

This document is up-to-date

Long-Acting Reversible Contraception (LARC)